Liraglutide Side Effects: 2026 Mid-Year Update

Liraglutide has now been on the market for more than 15 years — exenatide-replacement-as-Victoza since 2010 for type 2 diabetes, Saxenda for obesity since 2014 — which makes its safety dataset the longest of any GLP-1 receptor agonist currently in routine use.¹ In a class where the next-generation agents (semaglutide, tirzepatide, retatrutide) are still accumulating long-term data, liraglutide is the closest thing to a benchmark. This mid-2026 update reviews the side-effect profile across GI, cardiovascular, oncology, and pancreatic axes; weights the long-term real-world signals against the trial data; and compares the tolerability profile against the newer agents in the class.

This post is a deep-dive on side effects specifically — for the structured catalog with severity ratings and frequency data, see the liraglutide side-effects page. For dosing and titration mechanics, see the liraglutide dosing protocols.

Background: What Liraglutide Is and How Adverse Events Arise#

Liraglutide is a once-daily, subcutaneously injected GLP-1 receptor agonist with approximately 97% homology to native human GLP-1, modified with a C-16 fatty acid side chain that promotes albumin binding and extends the half-life to roughly 13 hours.² Its mechanism — GLP-1 receptor agonism in pancreatic beta cells, gut, and central nervous system — is the source of both its therapeutic effects (incretin-driven insulin secretion, gastric emptying delay, central satiety signaling) and its dominant adverse-event class (gastrointestinal effects driven by delayed gastric emptying and central nausea-pathway activation).

Most of the side-effect profile is mechanistic, not idiosyncratic. This is important because it means the tolerability profile is largely predictable from the dose-response curve, and the escalation schedule was designed specifically to minimize the GI burden — not as an afterthought.

Most Common Side Effects: GI Tolerability#

The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015), which enrolled 3,731 adults with BMI ≥30 (or ≥27 with comorbidity) and randomized them to liraglutide 3.0 mg vs placebo, established the canonical adverse-event distribution for liraglutide at obesity dosing:³

• Nausea: 39.3% in the liraglutide arm versus 13.8% in the placebo arm.
• Diarrhea: 20.9% vs 9.9%.
• Constipation: 19.4% vs 8.5%.
• Vomiting: 15.7% vs 3.6%.
• Dyspepsia: 9.6% vs 2.7%.

The same study reported that GI events were largely mild-to-moderate, transient, and concentrated in the dose-escalation period. Approximately 9.9% of patients in the liraglutide arm discontinued because of adverse events versus 3.8% in the placebo arm — a discontinuation gap of roughly 6 percentage points attributable to drug-related AE burden.³

The SCALE Diabetes trial (Davies et al., 2015), in patients with type 2 diabetes, showed a qualitatively similar distribution: nausea was again the dominant event, present in approximately 33% of the liraglutide 3.0 mg arm, with comparable rates of vomiting and diarrhea.⁴

The dose-escalation schedule for obesity (0.6 mg → 1.2 mg → 1.8 mg → 2.4 mg → 3.0 mg, advancing weekly) was designed to mitigate this. Real-world experience confirms that GI tolerability improves substantially after the first 4–8 weeks at target dose — though the data on exactly how much improvement and how durable it is across multi-year use comes more from post-marketing analyses than from the registrational trials themselves.⁵

For practical comparison against the rest of the class, the GLP-1 side effects comparison post benchmarks liraglutide against semaglutide, tirzepatide, and the newer agents on the same axes.

Cardiovascular Safety: The LEADER Trial#

LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) is the single most important safety study in the liraglutide dataset and one of the foundational trials for the entire GLP-1 class. Marso et al. randomized 9,340 patients with type 2 diabetes and either established cardiovascular disease or high CV risk to liraglutide (up to 1.8 mg daily) versus placebo, with a median follow-up of 3.8 years.⁶

Key results:

• Primary composite outcome (CV death, nonfatal MI, nonfatal stroke): 13.0% in liraglutide versus 14.9% in placebo. Hazard ratio 0.87 (95% CI 0.78–0.97), p<0.001 for non-inferiority and p=0.01 for superiority.⁶
• Cardiovascular death: 4.7% liraglutide versus 6.0% placebo. HR 0.78 (0.66–0.93), p=0.007.⁶
• All-cause mortality: 8.2% versus 9.6%. HR 0.85 (0.74–0.97), p=0.02.⁶

The result was practice-changing. Liraglutide became the first GLP-1 receptor agonist with demonstrated CV outcome benefit in a dedicated cardiovascular outcomes trial, and the data supported subsequent FDA label updates and ADA/EASD consensus recommendations to prefer GLP-1 RAs with proven CV benefit in patients with established atherosclerotic cardiovascular disease.⁷

Subsequent meta-analyses including liraglutide alongside semaglutide and other GLP-1 RAs have generally confirmed a class effect for MACE reduction in patients with established ASCVD,⁸ although the magnitude varies by agent and population.

Oncology Concerns: The Thyroid Black-Box Warning#

Liraglutide carries an FDA black-box warning for medullary thyroid carcinoma (MTC) risk based on rodent carcinogenicity studies showing dose- and duration-dependent thyroid C-cell tumor formation in mice and rats.⁹ The drug is contraindicated in patients with personal or family history of MTC and in patients with multiple endocrine neoplasia syndrome type 2 (MEN-2).

The human translation of the rodent signal remains an open question. Post-marketing surveillance through 2026 has not produced a clearly demonstrated increase in MTC incidence attributable to liraglutide in human populations,¹⁰ but the warning has been retained because the signal in rodents is robust and the latency for human MTC could exceed the observation window of available data. The pragmatic clinical position is that the warning is taken seriously for the relatively small population it identifies (personal or family MTC history; MEN-2) and is not considered a class-wide barrier for the broader at-risk population.

The same C-cell tumor signal has been identified for semaglutide and tirzepatide and carries forward as a class warning.

Pancreatic Safety: Acute Pancreatitis#

A numerically higher rate of acute pancreatitis was observed in liraglutide arms versus placebo across the SCALE obesity program (approximately 0.4% vs <0.1% in SCALE Obesity).³ Absolute rates are low, but the signal is consistent across the GLP-1 class and is mentioned in the FDA-approved labeling as an adverse event of clinical concern.

The LEADER trial did not show a statistically significant excess of pancreatitis in the liraglutide arm,⁶ which has tempered initial concerns from the earlier exenatide post-marketing data. The current clinical position is that acute pancreatitis is a recognized but uncommon adverse event; the drug is typically discontinued and not re-initiated in patients who develop pancreatitis on therapy, and is not initiated in patients with active or recent pancreatitis.

Gallbladder Disease and Cholelithiasis#

GLP-1 receptor agonists as a class have been associated with increased gallbladder events, including cholelithiasis and cholecystitis, particularly at obesity dosing where weight loss itself is a known cholelithiasis risk factor. Liraglutide 3.0 mg in the SCALE program showed cholelithiasis in approximately 2.5% of patients versus 1.0% on placebo.³

The current understanding is that the gallbladder signal reflects both a direct GLP-1 receptor effect on gallbladder motility and the indirect contribution of rapid weight loss. The risk is manageable but worth pre-counseling, particularly in patients with a history of gallstones.

Long-Term Real-World Safety Signals#

Post-marketing data from the SCALE follow-up extensions and large observational databases through 2025 have not produced a major new safety signal beyond what the registrational program identified.¹¹ The dominant long-term concerns remain:

1. Discontinuation rates — meaningful proportions of patients stop the drug because of tolerability, not safety. Real-world adherence at 12 months is materially lower than trial adherence.
2. Weight regain on discontinuation — once the drug is stopped, most of the weight loss is recovered within 12–24 months, which has implications for how the drug is positioned (chronic therapy vs short-term intervention).
3. No clear oncology signal beyond the C-cell warning — pancreatic cancer concerns from the exenatide era have not materialized in liraglutide-specific post-marketing analyses.¹⁰

Head-to-Head Tolerability: Liraglutide vs The Newer GLP-1s#

Versus Semaglutide#

The SUSTAIN-10 trial directly compared semaglutide 1.0 mg weekly versus liraglutide 1.2 mg daily in type 2 diabetes patients and showed that semaglutide produced greater HbA1c reduction (-1.7% vs -1.0%) and greater weight loss (-5.8 kg vs -1.9 kg), but at the cost of more nausea (43.9% vs 33.4%) and more discontinuations for GI events.¹² At matched dose intensity, the two drugs behave similarly per mg, but semaglutide's higher achievable plateau dose produces more event density.

For a direct comparison post, see liraglutide vs semaglutide.

Versus Tirzepatide#

No registrational head-to-head trial of liraglutide versus tirzepatide exists, but indirect comparison through network meta-analysis and the SURPASS and STEP program data suggests tirzepatide produces greater efficacy with broadly similar tolerability per unit of achieved weight loss.¹³ The dual GIP/GLP-1 mechanism of tirzepatide may attenuate some of the pure-GLP-1 nausea burden at matched efficacy, though the data are not conclusive.

See liraglutide vs tirzepatide for the structured comparison.

Versus Retatrutide#

Retatrutide's Phase 2 data show greater absolute weight loss than any agent in the class,¹⁴ with a tolerability profile that, on first inspection, looks broadly similar to other GLP-1 RAs at matched titration. The Phase 3 TRIUMPH registrational program is expected to clarify the long-term comparative safety,¹⁵ but as of mid-2026 the safety dataset is too small to make strong claims about advantages or disadvantages versus liraglutide.

Who Should Avoid Liraglutide#

The drug is contraindicated or strongly cautioned in:

• Personal or family history of medullary thyroid carcinoma or MEN-2 (black-box contraindication).
• History of pancreatitis (relative contraindication; class-wide caution).
• Severe gastroparesis or other significant GI motility disorders (mechanism amplifies symptoms).
• Pregnancy or planned pregnancy (insufficient safety data; alternative agents preferred).
• Patients unable to perform daily subcutaneous injection (a practical barrier — weekly agents may be preferable here).

For patients with significant ASCVD, the LEADER data make liraglutide one of the GLP-1 RAs with demonstrated CV benefit, which is a factor in agent selection. For patients prioritizing minimum injection burden, the daily-dosing requirement is a meaningful drawback relative to weekly semaglutide or tirzepatide.

Use the GLP-1 Saturation Calculator to model steady-state plasma concentration if you are evaluating switching between GLP-1 agents and want to understand the washout window. The Stack Compatibility Checker flags interactions if you are layering liraglutide with other peptides.

Bottom Line#

Liraglutide's side-effect profile is well-characterized, dominated by GI events that are largely predictable, dose-dependent, and concentrated in the escalation period. Its long real-world dataset is its biggest comparative advantage over the newer agents — there are no late-emerging signals in 15 years of post-marketing experience that change the basic risk-benefit picture. Its biggest comparative disadvantages are the daily injection burden and the somewhat lower achievable efficacy versus semaglutide and tirzepatide.

For patients who tolerate it and for whom daily injection is acceptable, liraglutide remains a reasonable GLP-1 choice with the best-documented long-term safety record in the class. For patients prioritizing maximum weight loss or minimum injection frequency, the newer agents generally win.

References#

Related Reading#

• Liraglutide overview
• Liraglutide side-effects catalog
• Liraglutide vs semaglutide comparison
• Liraglutide vs tirzepatide comparison
• GLP-1 side effects compared (full class)
• GLP-1 drugs ranked by weight loss
• Complete guide to GLP-1 receptor agonists

Footnotes#

1. U.S. Food and Drug Administration. Liraglutide (Victoza, Saxenda) approval history. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/. Victoza approved January 2010; Saxenda approved December 2014. ↩

2. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology. 2019;10:155. PMID: 31031702. DOI: 10.3389/fendo.2019.00155. ↩

3. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). New England Journal of Medicine. 2015;373(1):11-22. PMID: 26132939. DOI: 10.1056/NEJMoa1411892. ↩ ↩² ↩³ ↩⁴

4. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA. 2015;314(7):687-99. PMID: 26284720. DOI: 10.1001/jama.2015.9676. ↩

5. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity. 2013;37(11):1443-51. PMID: 23812094. DOI: 10.1038/ijo.2013.120. ↩

6. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). New England Journal of Medicine. 2016;375(4):311-22. PMID: 27295427. DOI: 10.1056/NEJMoa1603827. ↩ ↩² ↩³ ↩⁴ ↩⁵

7. Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the ADA and EASD. Diabetologia. 2020;63(2):221-228. PMID: 31853556. DOI: 10.1007/s00125-019-05039-w. ↩

8. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. The Lancet Diabetes & Endocrinology. 2021;9(10):653-662. PMID: 34425083. DOI: 10.1016/S2213-8587(21)00203-5. ↩

9. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473-86. PMID: 20203154. DOI: 10.1210/en.2009-1272. ↩

10. Hu W, Song R, Cheng R, et al. Use of GLP-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis. Frontiers in Endocrinology. 2022;13:927859. ↩ ↩²

11. U.S. FDA. Postmarketing Drug Safety Evaluation - liraglutide. Adverse Event Reporting System (FAERS) public dashboards. Available at: https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers. ↩

12. Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes & Metabolism. 2020;46(2):100-109. PMID: 31539622. DOI: 10.1016/j.diabet.2019.101117. ↩

13. Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251-1261. PMID: 35579691. DOI: 10.1007/s00125-022-05715-4. ↩

14. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526. PMID: 37366315. DOI: 10.1056/NEJMoa2301972. ↩

15. Giblin K, Boehnke A, Brown C, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism. 2026. PMID: 41090431. DOI: 10.1111/dom.70209. ↩